Document 2284
 DOCN  M94A2284
 TI    The preparation for AIDS vaccine efficacy trial in India.
 DT    9412
 AU    Rodrigues J; Mehendale S; Shephard M; Quinn T; Divekar A; Brookmeyer R;
       Gangakhedkar R; Gokhale M; Bollinger R; National AIDS Research Institute
       (ICMR), Pune, India.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):339 (abstract no. PC0290). Unique
       Identifier : AIDSLINE ICA10/94370291
 AB    In 1993, the first longitudinal study of HIV transmission in India was
       begun through the Preparation for HIV/Vaccine Efficacy (PAVE) Trials
       program of the NIAID. Since the Indian PAVE site began officially in May
       1993, 1870 high risk individuals have been screened from 2 STD clinics
       in Pune. 388 were HIV positive (20.7%) including 23 (1.2%) that were
       dually reactive for HIV-1 & HIV-2 & 4 (0.1%) for HIV-2 alone. Of
       screened individuals, 22.2% were female & 77.6% were male 67% women & 3%
       men were commercial sex workers. The mean age of participants was 26
       years for women & 27 years for men. The age-specific HIV-1
       seroprevalence rates for women were 27.7% (ages 14-19), 31.3% (20-24),
       34.6% (25-29), 31.2% (30+). The age-specific HIV-1 sevoprevalence rates
       for men were 12.8% (age 14-19), 22.1% (20-24), 25.2% (25-29), 17.3%
       (30+). 64% women reported no formal education, compared with 15% men.
       42% women & 55% men reported a history of genital ulcer disease & 80%
       men presented with an active STD. 9% of the women & 2% of the men
       reported a history of blood transfusion. Longitudinal follow-up of this
       cohort is underway to estimate HIV seroincidence & build the
       infrastructure, which may provide the basis for future HIV vaccine
       trials. Local community involvement & governmental support are vital in
       undertaking HIV vaccine trials.
 DE    Acquired Immunodeficiency Syndrome/EPIDEMIOLOGY/*PREVENTION &
       CONTROL/TRANSMISSION  Adolescence  Adult  AIDS Vaccines/*ADMINISTRATION
       & DOSAGE  Clinical Trials/*STATISTICS & NUMER DATA  *Developing
       Countries  Female  Follow-Up Studies  Human  HIV
       Infections/EPIDEMIOLOGY/*PREVENTION & CONTROL/TRANSMISSION  HIV
       Seroprevalence/*TRENDS  HIV-1/IMMUNOLOGY  HIV-2/IMMUNOLOGY
       India/EPIDEMIOLOGY  Longitudinal Studies  Male  Risk Factors  MEETING
       ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).